Wegovy Pill MHRA-Approved UK: Let’s dig into a bit more…

The Wegovy Pill has been approved in the UK. On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy tablets (oral semaglutide) for weight management, making it the first daily GLP 1 weight loss pill ever licensed in the UK. For the millions of people in the UK who are eligible for weight loss treatment but have been put off by weekly injections, this is the development they have been waiting for: the proven effects of semaglutide, in a once daily tablet. In this article, we explain exactly what has been approved, what the clinical trial results show, how the new tablet compares with the Wegovy injection and Mounjaro, when you will be able to get it, and how to be first in line when it launches at The Care Pharmacy.

What exactly has the MHRA approved?

The MHRA, the UK’s medicines regulator, has granted a licence for Wegovy tablets, a once daily oral form of semaglutide made by Novo Nordisk. The licence covers weight management in adults living with obesity, defined as a body mass index (BMI) of 30 or above, or adults who are overweight, with a BMI of 27 to under 30, who also have at least one weight related health condition such as high blood pressure, high cholesterol, type 2 diabetes risk, or sleep apnoea. As with all GLP 1 weight loss medicines, the licence requires the tablet to be used alongside a reduced calorie diet and increased physical activity, not instead of them.

This is a genuine first. While semaglutide has been available as a tablet for type 2 diabetes for several years under the brand name Rybelsus, the doses used for diabetes are much lower. The new Wegovy tablet goes up to a 25mg daily maintenance dose, the level shown in trials to deliver weight loss comparable to the weekly injection. The UK approval follows the United States, where the Wegovy pill was approved in December 2025 and launched to strong early demand.

What is the Wegovy Pill and how does it work?

The Wegovy Pill contains semaglutide, exactly the same active ingredient as the weekly Wegovy injection. Semaglutide is a GLP 1 receptor agonist: it mimics a natural gut hormone called GLP 1 that your body releases after eating. By activating GLP 1 receptors, semaglutide acts on appetite centres in the brain to reduce hunger and increase feelings of fullness, and it slows the rate at which your stomach empties, so smaller meals keep you satisfied for longer. For most people, the practical effect is that eating less stops feeling like a constant battle with willpower.

Getting a peptide medicine like semaglutide to survive the journey through the stomach is no small feat, which is why GLP 1 medicines have historically been injections. The Wegovy tablet solves this with an absorption enhancer that protects semaglutide from stomach acid and helps it pass through the stomach lining. It is also the reason the tablet comes with strict instructions about how to take it, which we cover below — taken incorrectly, much less of the medicine is absorbed and results suffer.

How effective is the Wegovy Pill? The OASIS 4 trial results

The MHRA approval is based on OASIS 4, a phase 3 clinical trial that studied the 25mg semaglutide tablet in 307 adults living with obesity, or overweight with at least one weight related condition, who did not have diabetes. The headline results after 64 weeks of treatment, alongside lifestyle changes, were striking. Participants taking the tablet lost on average around 13.6% of their body weight, compared with around 2.4% in the placebo group. Among participants who took the treatment exactly as intended, average weight loss reached around 16.6%, versus around 2.7% with placebo.

To put that in context, for someone weighing 100kg, that is an average loss in the region of 14 to 17kg over about 15 months. These figures are broadly in line with what the weekly 2.4mg Wegovy injection achieved in its own trials, which is exactly the point: the tablet is not a weaker convenience option, it is a comparable treatment in a different form. Side effects also looked familiar. Around 7% of trial participants stopped treatment because of adverse events, mostly gastrointestinal, which is consistent with the rates seen with injectable semaglutide.

Be first in line when the Wegovy Pill launches

The Wegovy Pill is now listed as Coming Soon on our Wegovy Pill product page, and we will begin taking orders as soon as UK launch stock is confirmed. Join the waitlist below and we will email you the moment it is available, along with confirmed pricing.

Dosing: how the Wegovy Pill is prescribed

The Wegovy Pill comes in four strengths: 1.5mg, 4mg, 9mg, and 25mg. Everyone starts on 1.5mg once daily, and the dose is increased step by step, with a minimum of one month at each level, until the 25mg maintenance dose is reached as tolerated. This gradual escalation is deliberate. GLP 1 medicines commonly cause nausea and other digestive side effects when the dose rises, and giving the body a month to adjust at each step keeps these manageable for most people.

There is one particularly interesting provision in the licence for existing patients: people already established on the 2.4mg weekly Wegovy injection can transition directly to the 25mg daily tablet, without restarting the dose ladder from the bottom, subject to clinical assessment. If you are currently injecting and have been waiting for a tablet option, the switch may be more straightforward than you expected — our prescriber will be able to review this with you once the tablet launches.

How to take the Wegovy Pill correctly

This is where the tablet demands more of you than the injection. Because semaglutide is absorbed through the stomach and food or drink dramatically reduce that absorption, the instructions are strict:

• Take one tablet first thing in the morning, on an empty stomach, when you wake up
• Swallow it whole with a small amount of plain water, up to about 120ml — never with any other drink, and never split, crushed, chewed, or dissolved
• Wait at least 30 minutes before eating, drinking anything else, or taking any other oral medicines
• If you miss a dose, skip that day and take your next dose at the usual time tomorrow — never double up
• Keep the tablets in their original closed bottle at room temperature, protected from moisture

In trials, people who did not follow the empty stomach routine absorbed less of the medicine and lost less weight, so this is not optional small print. It is the trade off for going needle free: a weekly injection you can take at any time, versus a daily tablet with a fixed morning ritual. Which suits you better depends entirely on your routine and preferences.

Wegovy Pill vs Wegovy injection vs Mounjaro: how do they compare?

The Wegovy injection remains the established form of semaglutide for weight management: one injection a week, at any time of day, with or without food, with average weight loss of around 15% in its pivotal trial and up to around 20% at the newer 7.2mg dose recently approved in the UK. The new tablet delivers broadly comparable results to the standard 2.4mg injection, in exchange for daily dosing and the strict morning routine.

Mounjaro (tirzepatide) is a different medicine altogether: a weekly injection that activates two gut hormone receptors, GLP 1 and GIP, rather than one. In clinical trials, tirzepatide delivered average weight loss of around 20% or more at higher doses, which is why it is currently our recommended first line option for most eligible patients. For now, Mounjaro remains injection only — although its own oral competitor, orforglipron, is in late stage development, as we covered in our recent blog on upcoming weight loss treatments.

The honest summary: if maximum weight loss is the priority, Mounjaro currently has the strongest trial results. If you want semaglutide specifically, the choice between pill and injection is about lifestyle, not effectiveness. And if needles have been the one thing stopping you from starting treatment at all, the Wegovy Pill removes that barrier entirely.

Will the Wegovy Pill be available on the NHS?

Not yet. MHRA approval means the medicine is licensed for use in the UK; it does not mean the NHS will fund it. Any NHS rollout depends on a cost effectiveness assessment by NICE, and even for the Wegovy injection, NHS access remains limited to specialist weight management services with strict criteria and long waiting lists. Realistically, regulated private pharmacies are expected to be the first route of access for the Wegovy Pill in the UK, just as they have been for the injectable treatments. That is exactly the service we provide: a GPhC registered UK pharmacy, with every order reviewed and approved by our prescriber following an online consultation.

When can you get it, and what will it cost?

Novo Nordisk has not yet confirmed the UK launch date or pricing for the Wegovy Pill, and we will not speculate on either. What we can say is that the US launch followed within weeks of approval there, and UK demand is expected to be very high — recent research suggests around 1.6 million people in the UK used Wegovy or Mounjaro in the past year, with millions more interested in starting treatment. We have listed the Wegovy Pill on our weight loss range as Coming Soon, and waitlist members will be the first to hear confirmed pricing and availability, with 10% off their first order.

What should you do in the meantime?

If you are eligible for weight loss treatment and ready to start now, there is no clinical reason to wait for the tablet. The Mounjaro weight loss injection and Wegovy injection are both available today from The Care Pharmacy following a free online consultation, and both have strong, well established trial results. If you later decide the daily tablet suits you better, switching is something our prescriber can review with you once it launches. And if injections are simply not for you, join the waitlist above, and in the meantime focus on the foundations that make any GLP 1 treatment work better: nutrition, regular movement, sleep, and sustainable habits.

The bottom line

The MHRA approval of the Wegovy Pill is a landmark moment for weight management in the UK. For the first time, a GLP 1 medicine with double digit average weight loss is available in a once daily tablet, removing the single biggest barrier — needles — that has kept many eligible people from starting treatment. It is not a shortcut, it demands a disciplined morning routine, and it still only works alongside real lifestyle change under medical supervision. But as an option, it meaningfully widens the door. Join the waitlist on this page or on the Wegovy Pill product page, and we will let you know the moment it arrives.

The Wegovy Pill is a prescription only medicine. A clinical assessment is required, and treatment is only suitable where a prescriber decides it is clinically appropriate. GLP 1 medicines are not intended for short term cosmetic weight loss and should only be used under medical supervision. Information in this article is correct as of 12 June 2026 and will be updated when UK prescribing information and pricing are confirmed.